WuXi Biologics (Cayman) revenue and financials
$56.70Change from previous close: −2.07%Absolute change: −$1.20
In the fiscal year ended December 2025, WuXi Biologics (Cayman) reported revenue of ¥21.79B (+16.68% year over year). Net income was ¥4.91B, a net margin of 22.5%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +16.68%
- 2025 vs 2024
- Net income growth
- +46.25%
- 2025 vs 2024
- Net margin
- 22.5%
- 2024: 18.0%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 6,341 | 5,217 | 4,668 | 5,542 | 3,431 |
| Depreciation and amortization | 1,448 | 1,437 | 1,169 | 801 | 482 |
| Capital expenditure | -3,685 | -3,930 | -4,046 | -5,868 | -6,508 |
| Investing cash flow | -3,087 | -3,942 | -3,228 | -5,908 | -9,602 |
| Financing cash flow | -2,164 | -2,750 | 1,961 | -2,592 | 8,209 |
| Share repurchases | -1,577 | -1,766 | -917 | -2,804 | -2,517 |
| Debt issued | 1,122 | 1,129 | 1,097 | 2,389 | 675 |
| Debt repaid | -2,901 | -819 | -1,916 | -2,684 | -822 |
| Effect of exchange rates | -155 | 84.0 | -126 | 350 | -132 |
| Net change in cash | 935 | -1,391 | 3,275 | -2,608 | 1,908 |
| Free cash flow | 2,656 | 1,288 | 622 | -327 | -3,077 |
| Levered free cash flow | 4,284 | -2,296 | -320 | -594 | -3,720 |